294 related articles for article (PubMed ID: 19144995)
1. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.
Hamai H; Keyserman F; Quittell LM; Worgall TS
J Lipid Res; 2009 Jun; 50(6):1101-8. PubMed ID: 19144995
[TBL] [Abstract][Full Text] [Related]
2. Lipid metabolism in cystic fibrosis.
Worgall TS
Curr Opin Clin Nutr Metab Care; 2009 Mar; 12(2):105-9. PubMed ID: 19209467
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.
Mingione A; Dei Cas M; Bonezzi F; Caretti A; Piccoli M; Anastasia L; Ghidoni R; Paroni R; Signorelli P
Cell Physiol Biochem; 2020 Jan; 54(1):110-125. PubMed ID: 31999897
[TBL] [Abstract][Full Text] [Related]
4. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR).
Caohuy H; Yang Q; Eudy Y; Ha TA; Xu AE; Glover M; Frizzell RA; Jozwik C; Pollard HB
J Biol Chem; 2014 Dec; 289(52):35953-68. PubMed ID: 25384981
[TBL] [Abstract][Full Text] [Related]
5. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
[TBL] [Abstract][Full Text] [Related]
6. Sphingolipid synthetic pathways are major regulators of lipid homeostasis.
Worgall TS
Adv Exp Med Biol; 2011; 721():139-48. PubMed ID: 21910087
[TBL] [Abstract][Full Text] [Related]
7. CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis.
Noe J; Petrusca D; Rush N; Deng P; VanDemark M; Berdyshev E; Gu Y; Smith P; Schweitzer K; Pilewsky J; Natarajan V; Xu Z; Obukhov AG; Petrache I
Am J Respir Cell Mol Biol; 2009 Sep; 41(3):314-23. PubMed ID: 19168702
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory role of extracellular sphingolipids in Cystic Fibrosis.
Zulueta A; Peli V; Dei Cas M; Colombo M; Paroni R; Falleni M; Baisi A; Bollati V; Chiaramonte R; Del Favero E; Ghidoni R; Caretti A
Int J Biochem Cell Biol; 2019 Nov; 116():105622. PubMed ID: 31563560
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis.
Fang D; West RH; Manson ME; Ruddy J; Jiang D; Previs SF; Sonawane ND; Burgess JD; Kelley TJ
Respir Res; 2010 May; 11(1):61. PubMed ID: 20487541
[TBL] [Abstract][Full Text] [Related]
10. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
[TBL] [Abstract][Full Text] [Related]
11. Turnover of the cystic fibrosis transmembrane conductance regulator (CFTR): slow degradation of wild-type and delta F508 CFTR in surface membrane preparations of immortalized airway epithelial cells.
Wei X; Eisman R; Xu J; Harsch AD; Mulberg AE; Bevins CL; Glick MC; Scanlin TF
J Cell Physiol; 1996 Aug; 168(2):373-84. PubMed ID: 8707873
[TBL] [Abstract][Full Text] [Related]
12. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between CFTR and sphingolipids in cystic fibrosis.
Dobi D; Loberto N; Bassi R; Pistocchi A; Lunghi G; Tamanini A; Aureli M
FEBS Open Bio; 2023 Sep; 13(9):1601-1614. PubMed ID: 37315117
[TBL] [Abstract][Full Text] [Related]
14. The ORMDL/Orm-serine palmitoyltransferase (SPT) complex is directly regulated by ceramide: Reconstitution of SPT regulation in isolated membranes.
Davis DL; Gable K; Suemitsu J; Dunn TM; Wattenberg BW
J Biol Chem; 2019 Mar; 294(13):5146-5156. PubMed ID: 30700557
[TBL] [Abstract][Full Text] [Related]
15. Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR.
Benedetto R; Ousingsawat J; Cabrita I; Pinto M; Lérias JR; Wanitchakool P; Schreiber R; Kunzelmann K
J Mol Med (Berl); 2019 May; 97(5):711-722. PubMed ID: 30915480
[TBL] [Abstract][Full Text] [Related]
16. Endothelial Sphingolipid De Novo Synthesis Controls Blood Pressure by Regulating Signal Transduction and NO via Ceramide.
Cantalupo A; Sasset L; Gargiulo A; Rubinelli L; Del Gaudio I; Benvenuto D; Wadsack C; Jiang XC; Bucci MR; Di Lorenzo A
Hypertension; 2020 May; 75(5):1279-1288. PubMed ID: 32172624
[TBL] [Abstract][Full Text] [Related]
17. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis.
Yu H; Zeidan YH; Wu BX; Jenkins RW; Flotte TR; Hannun YA; Virella-Lowell I
Am J Respir Cell Mol Biol; 2009 Sep; 41(3):367-75. PubMed ID: 19168701
[TBL] [Abstract][Full Text] [Related]
18. Exploiting species differences to understand the CFTR Cl- channel.
Bose SJ; Scott-Ward TS; Cai Z; Sheppard DN
Biochem Soc Trans; 2015 Oct; 43(5):975-82. PubMed ID: 26517912
[TBL] [Abstract][Full Text] [Related]
19. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema.
Bodas M; Min T; Mazur S; Vij N
J Immunol; 2011 Jan; 186(1):602-13. PubMed ID: 21135173
[TBL] [Abstract][Full Text] [Related]
20. Effects of cystic fibrosis and congenital bilateral absence of the vas deferens-associated mutations on cystic fibrosis transmembrane conductance regulator-mediated regulation of separate channels.
Mickle JE; Milewski MI; Macek M; Cutting GR
Am J Hum Genet; 2000 May; 66(5):1485-95. PubMed ID: 10762539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
